HK1207654A1 - Modified antibody regions and uses thereof - Google Patents

Modified antibody regions and uses thereof Download PDF

Info

Publication number
HK1207654A1
HK1207654A1 HK15108290.3A HK15108290A HK1207654A1 HK 1207654 A1 HK1207654 A1 HK 1207654A1 HK 15108290 A HK15108290 A HK 15108290A HK 1207654 A1 HK1207654 A1 HK 1207654A1
Authority
HK
Hong Kong
Prior art keywords
modified antibody
antibody regions
regions
modified
antibodies
Prior art date
Application number
HK15108290.3A
Other languages
English (en)
Chinese (zh)
Inventor
Gerhard Frey
Jay M. Short
Hwai Wen Chang
Original Assignee
Bioatla, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla, Llc filed Critical Bioatla, Llc
Publication of HK1207654A1 publication Critical patent/HK1207654A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15108290.3A 2012-04-27 2013-04-26 Modified antibody regions and uses thereof HK1207654A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
US201261639729P 2012-04-27
PCT/US2013/038538 WO2013163630A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Publications (1)

Publication Number Publication Date
HK1207654A1 true HK1207654A1 (en) 2016-02-05

Family

ID=49483948

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108290.3A HK1207654A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Country Status (13)

Country Link
US (2) US20150065690A1 (cg-RX-API-DMAC10.html)
EP (2) EP2841458A4 (cg-RX-API-DMAC10.html)
JP (1) JP6470170B2 (cg-RX-API-DMAC10.html)
KR (2) KR20200037434A (cg-RX-API-DMAC10.html)
CN (1) CN104428317B (cg-RX-API-DMAC10.html)
AU (3) AU2013251309B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014026740B1 (cg-RX-API-DMAC10.html)
CA (1) CA2871807C (cg-RX-API-DMAC10.html)
HK (1) HK1207654A1 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN08721A (cg-RX-API-DMAC10.html)
MX (2) MX360368B (cg-RX-API-DMAC10.html)
RU (1) RU2014147741A (cg-RX-API-DMAC10.html)
WO (1) WO2013163630A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329556B2 (en) 2014-05-13 2019-06-25 Bioatla, Llc Conditionally active biological proteins
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
CN116239693A (zh) * 2016-03-14 2023-06-09 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
KR20230051630A (ko) * 2018-10-31 2023-04-18 바이오아트라, 인코퍼레이티드 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도
CN113544153B (zh) * 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
WO2020185632A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
US20220308072A1 (en) 2019-08-12 2022-09-29 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
AR122480A1 (es) * 2020-05-21 2022-09-14 Cadila Healthcare Ltd VARIANTE DE LA Fc Y PREPARACIÓN DE LA MISMA
KR20230015365A (ko) 2020-05-22 2023-01-31 포르미콘 아게 Ace2 융합 단백질 및 이의 용도
WO2022090469A2 (en) 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
WO2022184854A2 (en) 2021-03-03 2022-09-09 Formycon Ag Formulations of ace2 fc fusion proteins
EP4437112A1 (en) 2021-11-24 2024-10-02 Formycon AG Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1562972B1 (en) * 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
WO2004041854A2 (en) 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
CA2618681C (en) * 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
CA2625619A1 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
ES2742268T3 (es) * 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
EP2282770B1 (en) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
NZ607480A (en) * 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
WO2013010927A1 (en) 2011-07-15 2013-01-24 Basell Poliolefine Italia S.R.L. Polyolefin strap comprising a random copolymer of propylene with 1-hexene
EP2762564B1 (en) * 2011-09-30 2020-09-16 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
AU2012366290A1 (en) * 2012-01-19 2014-08-07 Therapeutic Proteins International, LLC Stabilization of the anti-CD20 antibody Rituximab

Also Published As

Publication number Publication date
CA2871807C (en) 2022-10-04
EP2841458A4 (en) 2015-09-16
RU2014147741A (ru) 2016-06-20
CN104428317B (zh) 2018-08-28
EP3470433B1 (en) 2025-12-03
US10954288B2 (en) 2021-03-23
US20180186863A1 (en) 2018-07-05
BR112014026740A2 (pt) 2017-06-27
IN2014DN08721A (cg-RX-API-DMAC10.html) 2015-05-22
AU2017225111B2 (en) 2019-01-03
CN104428317A (zh) 2015-03-18
MX382840B (es) 2025-03-13
MX360368B (es) 2018-10-29
AU2019202229A1 (en) 2019-04-18
BR112014026740B1 (pt) 2022-10-04
AU2013251309A1 (en) 2014-10-30
US20150065690A1 (en) 2015-03-05
AU2019202229B2 (en) 2021-02-11
WO2013163630A1 (en) 2013-10-31
BR112014026740A8 (pt) 2021-06-15
MX2014012978A (es) 2015-02-05
KR20150008082A (ko) 2015-01-21
EP3470433A1 (en) 2019-04-17
AU2017225111A1 (en) 2017-09-28
AU2013251309B2 (en) 2017-06-22
JP6470170B2 (ja) 2019-02-13
KR20200037434A (ko) 2020-04-08
CA2871807A1 (en) 2013-10-31
JP2015515497A (ja) 2015-05-28
EP2841458A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
HK1207654A1 (en) Modified antibody regions and uses thereof
IL281731A (en) Humanized antibodies that recognize alpha-synuclein, preparations containing them and their uses
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
WO2011089183A3 (en) Anticoagulant antidotes
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
NZ703423A (en) Antibodies to tau
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
HK1218549A1 (zh) 新型抗体框架
HK1210620A1 (en) Multi-specific monoclonal antibodies
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2014150877A3 (en) Anti-tau antibodies and methods of use
WO2014165771A3 (en) Anti-il-4 antibodies and bispecific antibodies and uses thereof
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
EP3091030A4 (en) Anti-human rankl antibody, humanized antibody, pharmaceutical compositions and uses thereof
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
TN2013000388A1 (en) Anticoagulant antidotes
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
HK1214279A1 (zh) 組合物和相關的抗原結合蛋白針對il-21受體的方法
EP3066122A4 (en) Pre-haptoglobin-2 monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM BIOATLA LLC TO BIOATLA, LLC